
Bio-Path Holdings Inc (BPTH) shares were up dramatically today, and then they fell very, very quickly. The stock’s price rose from under $3 per share back in late February to over $70 per share. While the company did release a report claiming there BP1001 treatment demonstrated “meaningful clinical improvement”, this is a far cry from a definitive statement of proof of clinical efficacy. With this in mind, it seems clear that this news does not justify an over 20X price increase, so it is no surprise that shares dropped very sharply to nearly $27 after peaking over $70. Here’s a recap.